Zobrazeno 1 - 10
of 95
pro vyhledávání: ''
Autor:
Marc T. Goodman, Susan J. Jordan, Kathryn L. Terry, Joellen M. Schildkraut, Kirsten B. Moysich, Jennifer A. Doherty, Penelope M. Webb, Karen McLean, Linda Titus, Anna H. Wu, Holly R. Harris, Alice W. Lee, Malcolm C. Pike, Celeste Leigh Pearce, Andrew Berchuck, Gillian E. Hanley, Minh Tung Phung, Francesmary Modugno, Bhramar Mukherjee, Kathleen R. Cho, Daniel W. Cramer
Publikováno v:
Cancer Epidemiol Biomarkers Prev
Background: Combined oral contraceptive use is associated with a decreased risk of invasive epithelial ovarian cancer (ovarian cancer). There is suggestive evidence of an inverse association between progestin-only contraceptive use and ovarian cancer
Autor:
Alexander Melamed, Melissa Beauchemin, Melissa K. Accordino, Jason D. Wright, Dawn L. Hershman, Jacob C Cogan, Rohit R. Raghunathan
Publikováno v:
Cancer Research. 81:GS3-08
Introduction Cancer surgery has been linked to chronic opioid use post-operatively, with up to 10% of patients continuing to fill opioid prescriptions beyond 3 months after surgery. However, previous studies have not compared post-operative opioid us
Autor:
Yu-Ming Shen, Dejan Juric, Murat Akdere, Aleix Prat, Hope S. Rugo, Stephen Chia, Christina Arce, Florence Lerebours, Nicholas C. Turner, Eva Ciruelos, Pamela Drullinsky, Rafael Villanueva Vazquez
Publikováno v:
Cancer Research. 81:PD2-07
Introduction: Mutations in PIK3CA, which encodes the α-isoform of phosphatidylinositol 3-kinase (PI3Kα), occur in ~40% of patients (pts) with HR+, HER2- ABC and can contribute to endocrine resistance. Alpelisib (ALP), a PI3Kα-selective inhibitor a
Autor:
Brenda J. Weigel, Keith D. Wilner, David Hall, Charles G. Minard, Jennifer Foster, Peter C. Adamson, Stacey L. Berg, Elizabeth Fox, Susan M. Blaney, Stephan D. Voss, Yael P. Mosse, Frank M. Balis
Publikováno v:
Clinical Cancer Research. 27:3543-3548
Purpose: Anaplastic lymphoma kinase (ALK) aberrations are a promising target for patients with neuroblastoma. We assessed the activity of first-generation ALK inhibitor crizotinib in patients with no known curative treatments and whose tumors harbore
Autor:
Britta M. Jacobsen, Jessica Finlay-Schultz, Reema Wahdan-Alaswad, Susan M. Edgerton, Bryan R. Haugen, Hyunmin Kim, Carol A. Sartorius, Elizabeth A. Wellberg, Ann D. Thor, Bolin Liu, Aik Choon Tan, Hiba Salem
Publikováno v:
Clinical Cancer Research. 27:585-597
Purpose: Thyroid disease is a frequent comorbidity in women with breast cancer, and many require thyroid hormone replacement therapy (THRT). We postulated that THRT has a deleterious clinical effect mechanistically through hormonal interactions, nucl
Publikováno v:
Clin Cancer Res
Liver cancer is the fourth leading cause of cancer-related mortality worldwide and incidence is on the rise. Hepatocellular carcinoma (HCC) is the most common form of liver cancer, with a complex etiology and limited treatment options. The standard-o
Autor:
Charlotte Fribbens, Lucy Kilburn, Stephen R. D. Johnston, William J. Gradishar, Mitch Dowsett, Judith M Bliss, Aman U. Budzar, John F.R. Robertson, Claire Swift, Nicholas C. Turner, Stephen Chia, Gaia Schiavon, Isaac Garcia-Murillas, Matthew Beaney, Martine Piccart
Publikováno v:
Clinical Cancer Research. 26:5172-5177
Purpose: ESR1 mutations are acquired frequently in hormone receptor–positive metastatic breast cancer after prior aromatase inhibitors. We assessed the clinical utility of baseline ESR1 circulating tumor DNA (ctDNA) analysis in the two phase III ra
Autor:
William G. Nelson, Michael T. Marrone, Berrak Gumuskaya, Charles G. Drake, Fan Pan, Ian M. Thompson, Ibrahim Kulac, Jun O. Liu, Phyllis J. Goodman, Ines Benedetti, Lauren M. Hurwitz, M. Scott Lucia, Elizabeth A. Platz, Angelo M. De Marzo, Catherine M. Tangen, Javier A. Baena Del Valle, William B. Isaacs, Kathryn B. Arnold
Publikováno v:
Cancer Prev Res (Phila)
Aspirin and statin use may lower the risk of advanced/fatal prostate cancer, possibly by reducing intraprostatic inflammation. To test this hypothesis, we investigated the association of aspirin and statin use with the presence and extent of intrapro
Autor:
Scott H. Kaufmann, James N. Ingle, Paul E. Goss, Michael A. Walters, Cristina Correia, Bingshu E. Chen, Matthew E. Cuellar, Tanya L. Hoskin, Matthew J. Ellis, Liewei Wang, Bernhard Volz, Ravinder J. Singh, Vera J. Suman, Richard M. Weinshilboum, Barbara Goodnature, Junmei Cairns, Krishna R. Kalari, Tufia C. Haddad, Matthew P. Goetz, Zeruesenay Desta, Erin E. Carlson, Poulami Barman, Peter A. Fasching, Lois E. Shepherd
Publikováno v:
Clin Cancer Res
Purpose:To determine if the degree of estrogen suppression with aromatase inhibitors (AI: anastrozole, exemestane, letrozole) is associated with efficacy in early-stage breast cancer, and to examine for differences in the mechanism of action between
Autor:
Erik Bloomquist, Kirsten B. Goldberg, Shenghui Tang, Laleh Amiri-Kordestani, Suparna Wedam, Lola Fashoyin-Aje, Marc R. Theoret, Richard Pazdur, Rajeshwari Sridhara, Julia A. Beaver
Publikováno v:
Clinical Cancer Research. 26:1208-1212
On April 4, 2019, the FDA approved a supplemental new drug application for palbociclib (IBRANCE), to expand the approved indications in women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer (MBC) in combination